Harrow Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. (NASDAQ: HROW) on February 9, 2021. The filing discloses material information regarding the company's investment in Melt Pharmaceuticals, Inc. ("Melt"), a portfolio company in which Harrow holds a significant equity stake.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for Harrow Health, Inc. for the reporting period. The document focuses exclusively on a specific corporate event rather than periodic financial performance.
Material Changes and Events
- Melt Pharmaceuticals Phase 1 Results: On February 9, 2021, Melt Pharmaceuticals reported successful results from a Phase 1 study of its drug candidate MELT (a combination of midazolam and ketamine) for sedation and analgesia during cataract surgery.
- Study Objectives Met: The study established relative bioavailability, pharmacokinetic parameters, and absorption rates. The drug was reported as well-tolerated by patients.
- Future Timeline: Melt expects to commence its Phase 2 clinical study in the third quarter of 2021.
- Harrow's Stake: Harrow Health owns 3,500,000 shares of Melt common stock, representing approximately 44% of Melt's issued and outstanding voting interests.
- Royalty Rights: Harrow holds a mid-single digit royalty right on net sales of the MELT drug candidate.
Guidance, Outlook, and Risks
The filing incorporates by reference the full text of Melt's press release (Exhibit 99.1) for complete details. No specific financial guidance or risk factors unique to Harrow's operations were disclosed in this specific 8-K, other than the inherent risks associated with clinical trial progression for the portfolio company.
Key Facts for Investor Verification
- Verify the full text of the Melt Pharmaceuticals press release filed as Exhibit 99.1 for detailed clinical data.
- Confirm the current valuation of Harrow's 44% equity stake in Melt Pharmaceuticals.
- Monitor the timeline for Melt's Phase 2 clinical study initiation in Q3 2021.
- Review the specific terms of the "mid-single digit" royalty agreement on MELT net sales.